ACM
AVBP icon

Aquatic Capital Management’s ArriVent BioPharma AVBP Stock Holding History

Aquatic Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$368K Buy
10,598
+10,138
+2,204% +$299K 0.01% 875
2026
Q1 		$10.6K Sell
460
-11,844
-96% -$268K ﹤0.01% 1269
2025
Q4 		$248K Buy
+12,304
New +$256K 0.01% 942

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Aquatic Capital Management's AVBP Position: Q2 2026 in Review

Aquatic Capital Management increased its ArriVent BioPharma (AVBP) stake by 2,204% in Q2 2026, buying an estimated $299K and bringing the position to 10,598 shares worth $368K. The position accounts for 0.01% of the portfolio, ranked #875.

Aquatic Capital Management first reported a position in AVBP in Q4 2025 and has held it in 3 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Aquatic Capital Management held 10,598 shares of ArriVent BioPharma worth $368K as of Q2 2026.
  • Aquatic Capital Management bought 10,138 ArriVent BioPharma shares in Q2 2026, an estimated $299K.
  • ArriVent BioPharma made up 0.01% of Aquatic Capital Management's portfolio in Q2 2026, its #875 holding.
  • Aquatic Capital Management first reported a position in ArriVent BioPharma in Q4 2025 and has held it in 3 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.